Alvotech commenced a trial in July 2022 to compare AVT06 and Eylea for the treatment of adults with neovascular (wet) age-related macular degeneration. Credit: Richard Leung/Kings College Hospital / Community Eye Health / Flickr (Creative Commons)

Alvotech has signed an exclusive agreement with Polifarma to commercialise AVT06, a planned biosimilar to Eylea (aflibercept), in Turkey.

Alvotech will oversee the development and production of AVT06 while Polifarma will handle the market registration and commercialisation of the biosimilar candidate.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In July 2022, Alvotech commenced a trial to compare AVT06 and Eylea for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD).

The trial has been designed to assess the efficacy, safety and immunogenicity of the therapy combination in the targeted patients.

Alvotech chairman and CEO Robert Wessman stated: “It is a pleasure to join forces with Polifarma in the commercialisation of a potential therapy in eye disease.

See Also:

“We are committed to providing better patient access to affordable biologics, and this agreement will allow us to better serve the growing and important Turkish market.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The latest deal comes a month after Alvotech received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for its biologics licence application (BLA) for AVT02, a biosimilar to Humira (adalimumab).

Polifarma CEO Mehmet Asri stated: “Polifarma has been contributing to public health and the health sector in the world for 37 years with its motto of ‘We stand by life’.

“This agreement with Alvotech allows us to expand our portfolio and further strengthen our position in the ophthalmology area.”